Skip to main
PGEN
PGEN logo

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc's positive outlook is bolstered by the anticipated approval of PRGN-2012, a promising therapy for recurrent respiratory papillomatosis (RRP), which is expected to enhance awareness and improve diagnostic accuracy. The therapy's demonstrated efficacy, particularly its significant reduction in the need for surgeries among patients, supports its acceptance by specialists within the medical community. Additionally, there is a strong confidence in the likelihood of PRGN-2012 receiving regulatory approval by the upcoming PDUFA date of August 27, 2025, further underscoring the stock's favorable prospects.

Bears say

Precigen Inc. faces significant challenges in maintaining or growing its reported sales due to unfavorable broader market conditions and competitive dynamics, which raises concerns about the sustainability of its revenue. The company has a longstanding history of financial losses and lacks a proven track record of consistent profitability, further complicating its financial health. Additionally, the presence of balance sheet risks could hinder the company's ability to secure future funding or execute its business strategy effectively.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.